Paul Tudor Jones's TEVA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 650.0K shares of Teva Pharmaceutical Industries Limited (TEVA) worth $13.13 M, representing 0.02% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in TEVA, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2022, adding 689.9K shares. Largest reduction occurred in Q2 2023, reducing 472.3K shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2014 | +300,000 | New Buy | 300,000 | $52.84 |
| Q2 2014 | -300,000 | Sold Out | 300,000 | $0.00 |
| Q1 2015 | +550,000 | New Buy | 550,000 | $62.30 |
| Q2 2015 | -150,000 | Reduce 27.27% | 400,000 | $59.10 |
| Q3 2015 | -389,700 | Reduce 97.42% | 10,300 | $56.50 |
| Q4 2015 | +389,700 | Add 3783.50% | 400,000 | $65.64 |
| Q1 2016 | -389,218 | Reduce 97.30% | 10,782 | $53.52 |
| Q2 2016 | -10,782 | Sold Out | 10,782 | $0.00 |
| Q3 2016 | +5,930 | New Buy | 5,930 | $46.04 |
| Q4 2016 | -5,930 | Sold Out | 5,930 | $0.00 |
| Q4 2019 | +10,596 | New Buy | 10,596 | $9.82 |
| Q1 2020 | -496 | Reduce 4.68% | 10,100 | $9.01 |
| Q2 2020 | -10,100 | Sold Out | 10,100 | $0.00 |
| Q3 2020 | +10,174 | New Buy | 10,174 | $9.04 |
| Q4 2020 | -10,174 | Sold Out | 10,174 | $0.00 |
| Q1 2022 | +700,087 | New Buy | 700,087 | $9.39 |
| Q2 2022 | +415,000 | Add 59.28% | 1.12 M | $7.52 |
| Q3 2022 | +10,000 | Add 0.90% | 1.13 M | $8.07 |
| Q4 2022 | +21,032 | Add 1.87% | 1.15 M | $0.01 |
| Q1 2023 | +11,859 | Add 1.03% | 1.16 M | $0.01 |
| Q2 2023 | -472,253 | Reduce 40.78% | 685,725 | $7.53 |
| Q3 2023 | +208,776 | Add 30.45% | 894,501 | $10.20 |
| Q4 2023 | +61,836 | Add 6.91% | 956,337 | $10.44 |
| Q1 2024 | -11,288 | Reduce 1.18% | 945,049 | $14.11 |
| Q2 2024 | -90,048 | Reduce 9.53% | 855,001 | $16.25 |
| Q3 2024 | -40,000 | Reduce 4.68% | 815,001 | $18.02 |
| Q4 2024 | -365,000 | Reduce 44.79% | 450,001 | $22.04 |
| Q1 2025 | +247,456 | Add 54.99% | 697,457 | $15.37 |
| Q2 2025 | -47,457 | Reduce 6.80% | 650,000 | $16.76 |
Paul Tudor Jones's Teva Pharmaceutical Industries Limited Investment FAQs
Paul Tudor Jones first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q1 2014, acquiring 300,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Teva Pharmaceutical Industries Limited (TEVA) for 47 quarters since Q1 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q1 2022, adding 700,087 shares worth $6.57 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 650,000 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $13.13 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 1,157,978 shares, as reported at the end of Q1 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.